Gloucester Phase II T cell lymphoma data

Gloucester (Cambridge, Mass.) reported interim data from a Phase II trial of its FK228 in 46 patients with cutaneous T cell lymphoma (CTCL) and relapsed peripheral T cell lymphoma (PTCL). The company said 9 of 18 evaluable CTCL patients had an objective response, including three complete responses. In 20 evaluable patients with PTCL, five had partial responses. ...